
Renewed BARDA backing boosts J&J’s COVID-19 vaccine funding by $1bn
pharmafile | November 17, 2020 | News story | Manufacturing and Production, Research and Development | BARDA, COVID-19, J&J, JJ, Janssen, Vaccine
Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop a COVID-19 vaccine, part of that sum coming from the US Government.
In an expansion of its current partnership with the Biomedical Advanced Research and Development Authority (BARDA), J&J is set to receive an additional $454 million from the authority to fund its ongoing Phase 3 studies of its adenovirus-based vaccine candidate in a single-dose formulation – a key factor that sets it apart from rival therapies from Moderna and Pfizer and BioNTech.
J&J’s pharmaceutical arm Janssen has also committed to investing $604 million to help fund the trial, which aims to enrol 60,000 participants in total.
This latest cash injection adds to previous investment made by both parties, who both opted to invest equal sums to a total of $1 billion back in March.
J&J also launched its second global COVID-19 vaccine this week. This one, however, will focus on testing the candidate in a two-dose formulation.
Matt Fellows
Related Content

BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …

COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …






